List of Excipients in Branded Drug OCTREOTIDE

Generic Drugs Containing OCTREOTIDE

Company	Ingredient	NDC	Excipient
Fresenius Kabi USA LLC	octreotide acetate	63323-365	ACETIC ACID
Fresenius Kabi USA LLC	octreotide acetate	63323-365	SODIUM ACETATE
Fresenius Kabi USA LLC	octreotide acetate	63323-365	SODIUM CHLORIDE

What are the Most Frequently-Used Excipients in OCTREOTIDE?

# Of NDCs	Excipient
2	ACETIC ACID
2	SODIUM ACETATE
2	SODIUM CHLORIDE

Octreotide Excipient Strategy and Commercial Opportunities

Last updated: August 14, 2026

Octreotide is a mature peptide with three commercial formulation models: immediate-release injection, long-acting injectable microspheres, and oral capsules. The largest excipient opportunities are in oral peptide absorption, sustained-release depots, ready-to-use injectable presentations, and formulation platforms that reduce cold-chain, injection, and administration burdens.

The commercial landscape is divided among Novartis’ Sandostatin and Sandostatin LAR, generic octreotide injection manufacturers, and Chiesi’s Mycapssa oral capsules. Patent barriers are materially stronger for oral delivery and complex depot systems than for conventional octreotide acetate injection.

What octreotide products are commercially available?

Octreotide is a synthetic somatostatin analogue used primarily for acromegaly and symptoms associated with neuroendocrine tumors. Its short plasma half-life creates a formulation requirement: immediate-release products require repeated dosing, while sustained-release and oral systems need excipient-enabled control of exposure.

Product	Dosage form	Manufacturer or marketer	Primary excipient strategy	Main commercial use
Sandostatin	Subcutaneous or intravenous solution	Novartis	Aqueous buffered solution with mannitol and phenol	Acromegaly, carcinoid syndrome, VIPoma
Sandostatin LAR Depot	Intramuscular microsphere suspension	Novartis	Poly(lactide-co-glycolide), mannitol, carboxymethylcellulose, polysorbate 80	Long-term acromegaly and neuroendocrine tumor treatment
Generic octreotide acetate injection	Subcutaneous or intravenous solution	Multiple generic manufacturers	Similar aqueous peptide-injection platform	Lower-cost replacement for Sandostatin injection
Mycapssa	Oral delayed-release capsule	Chiesi	Lipid-based oral peptide delivery system	Maintenance treatment of acromegaly

Sandostatin injection was approved by the FDA in 1988. Sandostatin LAR Depot was approved in 1998. Mycapssa received FDA approval in 2020 as the first approved oral octreotide product in the United States.[1-3]

What excipients are used in octreotide formulations?

Immediate-release octreotide injection excipients

Sandostatin injection uses a relatively conventional aqueous formulation. The labeled inactive ingredients include lactic acid, mannitol, sodium bicarbonate, phenol, and water for injection.[1]

Each excipient has a defined functional role:

Excipient	Function in the formulation	Commercial significance
Lactic acid	Acidification and pH control	Supports peptide solubility and stability
Sodium bicarbonate	Buffer adjustment	Controls injectable pH and tolerability
Mannitol	Tonicity adjustment and bulking agent	Established parenteral excipient with broad supply
Phenol	Antimicrobial preservative	Supports multidose presentation
Water for injection	Vehicle	Standard sterile injectable medium

The opportunity in this segment is limited for differentiated excipient development. Generic manufacturers can generally reproduce the formulation with established compendial materials. Competitive value is more likely to come from container closure, prefilled syringes, low-sorbtion packaging, preservative-free presentations, and manufacturing efficiency.

Long-acting microsphere excipients

Sandostatin LAR Depot uses a biodegradable microsphere system based on poly(DL-lactide-co-glycolide), commonly abbreviated PLGA. The formulation also contains mannitol, sodium carboxymethylcellulose, and polysorbate 80. The product is supplied as a powder that is reconstituted before deep intramuscular injection.[2]

The excipient system controls:

• Octreotide loading and encapsulation efficiency
• Microsphere porosity
• Initial burst release
• Polymer erosion
• Duration of drug release
• Syringeability after reconstitution
• Local tolerability at the injection site

PLGA composition is a major formulation variable. A higher lactide content generally slows polymer degradation, while molecular weight, end-group chemistry, particle size, and drug loading affect release kinetics. These variables create room for formulation patents even when the active ingredient is off patent.

Commercial opportunities include:

1. Lower-burst octreotide microspheres.
2. Smaller injection volumes.
3. Improved reconstitution and reduced needle clogging.
4. Ready-to-use or dual-chamber presentations.
5. Longer intervals than four weeks.
6. Alternative biodegradable polymers.
7. Lower-cost manufacturing processes with equivalent pharmacokinetics.

The principal barrier is analytical and clinical comparability. A follow-on depot product must demonstrate more than chemical equivalence. Release profile, local tolerability, injection performance, and clinical exposure can all affect regulatory acceptance.

Oral capsule excipients

Mycapssa uses a lipid-based oral delivery system designed to improve intestinal absorption of octreotide. The capsule contains medium-chain glycerides and other lipid excipients that facilitate peptide transport across the gastrointestinal tract. The formulation is intended for delayed release in the small intestine, where absorption conditions are more favorable than in the stomach.[3]

The formulation approach addresses several biological barriers:

• Proteolytic degradation
• Poor epithelial permeability
• Low intrinsic oral bioavailability
• Variable gastric emptying
• Food effects
• Dose-to-dose absorption variability

The oral delivery system is the most commercially differentiated excipient platform in the octreotide market. The value does not come from the inactive ingredients individually. It comes from the combination of lipid composition, capsule design, release location, dosing instructions, and manufacturing process.

What excipient strategies offer the strongest commercial opportunity?

Lipid-based oral delivery

Lipid excipients have the highest strategic value because they can convert octreotide from an injectable maintenance therapy into an oral treatment. Suppliers with pharmaceutical-grade medium-chain triglycerides, glycerides, surfactants, and lipid blends can participate in:

• Oral octreotide products
• Oral peptide delivery platforms
• Gastrointestinal absorption enhancers
• Reformulated somatostatin analogues
• Oral biologic rescue formulations

The primary risks are food-effect variability, gastrointestinal tolerability, excipient oxidation, capsule compatibility, and supply consistency. A lipid blend must be controlled by composition and performance, not only by nominal excipient identity.

Biodegradable depot polymers

PLGA remains the most established excipient platform for long-acting octreotide. Commercial differentiation can arise from polymer architecture, particle engineering, and manufacturing controls.

Potential product concepts include:

• Six- to eight-week octreotide depots
• Lower-volume injections
• Subcutaneous rather than intramuscular delivery
• Microneedle-compatible depots
• In situ forming implants
• Polymer-lipid hybrid particles

The technical challenge is balancing sustained release with peptide stability. Octreotide can be exposed to acidic microenvironments generated during PLGA degradation. Protein aggregation, acylation, incomplete release, and particle heterogeneity can reduce product performance.

Mucoadhesive and permeation-enhancing systems

Chitosan derivatives, thiolated polymers, cell-penetrating excipients, and enzyme-inhibiting systems may improve mucosal uptake. These technologies have commercial relevance, but their regulatory risk is higher than for conventional lipid excipients.

The strongest opportunity is likely a system that improves absorption without relying on a highly irritating permeation enhancer. Local epithelial damage, immunogenicity, and variable absorption can restrict development.

Ready-to-use injectable presentations

The immediate-release injectable market is mature, but presentation improvements can create smaller commercial opportunities. Relevant excipient and packaging strategies include:

• Preservative-free single-dose syringes
• Low-volume autoinjectors
• Stable prefilled cartridges
• Reduced adsorption to glass or polymer surfaces
• Improved cold-chain robustness
• Formulations compatible with home administration

These products are more likely to compete through convenience and adherence than through composition-of-matter exclusivity.

How does Mycapssa compare with Sandostatin LAR?

Mycapssa and Sandostatin LAR compete on administration burden rather than identical formulation characteristics.

Factor	Mycapssa	Sandostatin LAR
Route	Oral	Intramuscular
Dosing burden	Twice daily in the approved regimen	Generally every four weeks
Key excipient technology	Lipid-based intestinal delivery	PLGA microspheres
Manufacturing complexity	Lipid fill and delayed-release capsule	Sterile microsphere production and reconstitution
Patient burden	Daily adherence and food-related administration requirements	Periodic clinic injection
Main differentiation	Avoids injections	Reduces dosing frequency
Principal risk	Variable gastrointestinal absorption	Injection burden and depot manufacturing complexity
Follow-on barrier	Formulation, pharmacokinetic and clinical-performance patents	Microsphere composition and process patents

Mycapssa is commercially attractive where patients prioritize avoiding injections. Sandostatin LAR remains attractive where adherence to a monthly clinic-administered regimen is more reliable than daily oral dosing.

What patents protect octreotide formulations?

The original octreotide active-ingredient and conventional injection protection has expired in the United States. The remaining patent value is concentrated in formulation, delivery, manufacturing, and method-of-use claims.

Immediate-release injection patents

Generic octreotide acetate injections have entered the U.S. market because the core active-ingredient protection and early product exclusivities have expired. The most relevant barriers are typically:

• Injectable formulation claims
• Container-closure claims
• Method-of-use patents
• Labeling restrictions
• Manufacturing controls

These barriers are generally weaker than the formulation barriers around oral and long-acting products.

Sandostatin LAR patent estate

The LAR product is protected, where applicable, through claims directed to:

• Octreotide-loaded biodegradable microspheres
• Polymer composition and molecular weight
• Drug-to-polymer ratios
• Particle-size distribution
• Release profiles
• Reconstitution media
• Injection methods

Because the product is a complex drug-device and formulation system, an abbreviated generic pathway may be more difficult than a conventional injectable pathway. Follow-on manufacturers may need to develop a 505(b)(2) product or another pathway depending on the proposed formulation and evidence package.

Mycapssa patent estate

Mycapssa’s protection is concentrated in oral delivery technology rather than octreotide itself. Relevant claim categories include:

• Oral octreotide compositions
• Lipid excipient combinations
• Capsule dosage forms
• Delayed-release delivery
• Administration with food restrictions
• Methods for maintaining acromegaly control after injectable therapy
• Manufacturing and fill processes

Mycapssa also benefited from orphan-drug exclusivity for acromegaly following its 2020 approval. Orphan exclusivity generally runs for seven years from approval, placing the principal U.S. exclusivity period through approximately August 2027, subject to the scope of the approved indication and statutory exceptions.[3,4]

Public patent databases and FDA Orange Book entries should be reviewed before relying on a specific patent number, expiration date, or Paragraph IV conclusion. Formulation patents can have terminal disclaimers, patent-term adjustments, pediatric extensions, or claims that cover only a subset of the approved product.

When does octreotide lose exclusivity?

The core octreotide market has already lost exclusivity. The relevant commercial timetable is product-specific.

Milestone	Approximate date	Commercial effect
Sandostatin injection FDA approval	1988	Established the original injectable market
Sandostatin LAR Depot FDA approval	1998	Established monthly depot treatment
Core octreotide protection	Expired	Enabled generic immediate-release injection competition
Mycapssa FDA approval	August 2020	Created an oral octreotide market
Mycapssa orphan exclusivity	Approximately August 2027	Limits approval of the same drug for the same orphan indication
Mycapssa formulation patents	Potentially beyond orphan exclusivity	May delay oral generic or 505(b)(2) competition

Orphan exclusivity is separate from patent protection. A patent may continue after orphan exclusivity ends, while a patent challenge does not necessarily remove statutory orphan protection.

Which companies are challenging octreotide exclusivity?

Generic manufacturers have challenged the conventional injectable market through abbreviated applications. Competition is most established for octreotide acetate injection.

The higher-value challenges are likely to target:

• Sandostatin LAR Depot through complex injectable development
• Mycapssa through oral octreotide formulations
• Alternative oral somatostatin analogues
• Follow-on products with lower administration frequency
• Hybrid products using different delivery technologies

A conventional generic injection can compete on price. An oral or depot follow-on product must compete on formulation performance, regulatory pathway, clinical evidence, and intellectual-property clearance.

What is the FDA regulatory status of octreotide formulations?

The FDA has approved octreotide in injectable and oral dosage forms. The regulatory route depends on whether the proposed product duplicates the reference formulation or uses a materially different delivery system.

Likely regulatory pathways

Product concept	Potential pathway	Main evidence burden
Same-strength octreotide injection	ANDA	Pharmaceutical equivalence, bioequivalence, quality
Modified injectable formulation	505(b)(2)	Bridging studies, safety, pharmacokinetics
Follow-on microsphere depot	505(b)(2) or complex generic strategy	Release, exposure, local tolerance, clinical bridging
Oral lipid-based octreotide	505(b)(2) or new drug application	Food effect, pharmacokinetics, efficacy and safety
New oral peptide platform	New drug application	Full formulation and clinical development package

Excipient changes can alter the regulatory classification. A new permeation enhancer, novel polymer, or modified release system may require dedicated safety and clinical studies even when the active ingredient is unchanged.

What manufacturing and intellectual-property barriers affect octreotide?

The principal manufacturing barriers differ by dosage form.

Injection

Manufacturing barriers are moderate. Key controls include peptide purity, pH, sterility, preservative concentration, particulate matter, adsorption, and container compatibility.

Microspheres

Manufacturing barriers are high. Critical process parameters include:

• Emulsion formation
• Solvent removal
• Particle-size control
• Peptide distribution within particles
• Residual solvent
• Aseptic processing
• In vitro-in vivo release correlation
• Reconstitution performance

Small process changes can produce clinically relevant release differences.

Oral lipid capsules

Manufacturing barriers are also high. Key issues include:

• Lipid homogeneity
• Oxidative stability
• Encapsulation accuracy
• Capsule-seal integrity
• Delayed-release coating performance
• Drug precipitation after dispersion
• Food-effect control
• In vitro absorption prediction

The strongest IP position generally combines composition claims with manufacturing and method-of-use claims. A single narrow composition patent is more vulnerable to design-around than a portfolio covering lipid ratios, dosage form, dosing conditions, and treatment methods.

What generic launch scenarios exist for octreotide?

Low-risk scenario: injectable price erosion

Generic octreotide injection continues to reduce prices and margins for conventional presentations. This is the most predictable competitive outcome.

Medium-risk scenario: follow-on depot

A follow-on microsphere product may enter through a complex generic or 505(b)(2) strategy. Launch timing depends on patent litigation, FDA review, clinical bridging, and manufacturing readiness.

Higher-risk scenario: oral formulation challenge

An oral octreotide competitor must address formulation patents, orphan exclusivity, food effects, and clinical performance. The likely strategy is not a simple copy. It may involve a new lipid blend, a different capsule technology, or a different oral somatostatin analogue.

Substitution scenario: competing long-acting analogues

Lanreotide and other long-acting somatostatin analogues compete with octreotide on injection interval, device, administration setting, and payer positioning. A differentiated depot or oral product can compete without directly replicating Sandostatin LAR.

What commercial opportunities exist for excipient suppliers?

The strongest opportunities are in platform technologies that can be reused across peptide products.

Opportunity	Commercial attractiveness	Main development risk
Pharmaceutical-grade lipid blends	High	Absorption variability and food effects
PLGA microsphere platforms	High	Scale-up and release reproducibility
Ready-to-use injectable systems	Medium	Limited differentiation and price pressure
Mucoadhesive oral systems	Medium	Local tolerability and regulatory burden
Permeation enhancers	Medium to high	Safety and dose variability
Oxidation-resistant capsule excipients	Medium	Stability and packaging requirements
Subcutaneous depot polymers	High	Novel route and clinical bridging

Excipient suppliers can improve commercial defensibility by offering more than raw materials. The higher-value model includes formulation know-how, analytical methods, design-space data, stability packages, and regulatory support.

How strong is the octreotide patent estate?

The estate is strong for differentiated delivery systems and weak for the mature active ingredient and basic injection.

Asset category	Patent strength	Generic vulnerability
Octreotide active ingredient	Low	High
Conventional aqueous injection	Low to moderate	High
PLGA microsphere depot	Moderate to high	Moderate
Oral lipid-based capsule	High	Lower before key patents and exclusivities expire
Method of use	Moderate	Depends on label and claim scope
Manufacturing process	Moderate	Design-around possible
Excipient composition	Moderate to high	Depends on breadth and enablement

A commercial diligence review should separate statutory exclusivity, listed patents, unlisted patents, regulatory exclusivity, and practical manufacturing barriers. These categories do not expire at the same time.

Key Takeaways

• Octreotide has three major formulation markets: immediate-release injection, PLGA depot injection, and oral lipid-based capsules.
• Generic competition is established in conventional octreotide acetate injection.
• The strongest excipient opportunities are oral peptide delivery and long-acting biodegradable depots.
• Sandostatin LAR depends on PLGA microsphere engineering, while Mycapssa depends on lipid-mediated intestinal absorption.
• Mycapssa’s orphan exclusivity for acromegaly is expected to run approximately through August 2027, separate from any continuing patent protection.
• Formulation, manufacturing, release-profile, and method-of-use patents are more important than active-ingredient patents in the remaining octreotide market.
• Commercial opportunities are strongest for excipient suppliers that provide formulation platforms and regulatory evidence rather than commodity materials.
• Follow-on injection products face price competition. Follow-on oral and depot products face higher technical and IP barriers but offer greater value potential.

FAQs About Octreotide Excipients and Market Entry

Which excipient is most important in oral octreotide delivery?

The lipid excipient system is central because it supports intestinal absorption of the peptide. The commercial value lies in the optimized combination and performance, not in any single lipid material.

Can PLGA be used to develop a generic version of Sandostatin LAR?

Yes, but a PLGA microsphere product must address release kinetics, particle characteristics, peptide stability, reconstitution, local tolerability, and regulatory comparability. It is substantially more complex than a conventional octreotide injection.

Is octreotide acetate still protected by a composition-of-matter patent?

The original active-ingredient protection has expired in the United States. Current barriers are primarily formulation, delivery, manufacturing, method-of-use, and regulatory exclusivity rights.

Does Mycapssa require food restrictions because of its excipients?

Yes. Oral octreotide absorption is sensitive to administration conditions, and the approved labeling includes specific administration instructions intended to control exposure variability.[3]

Which octreotide product offers the largest excipient licensing opportunity?

Oral octreotide and next-generation depot formulations offer the largest licensing potential. Conventional injection excipients are widely available and generally provide limited platform differentiation.

References

1. Novartis Pharmaceuticals Corporation. (2023). Sandostatin (octreotide acetate) injection prescribing information. U.S. Food and Drug Administration.

2. Novartis Pharmaceuticals Corporation. (2023). Sandostatin LAR Depot (octreotide acetate) prescribing information. U.S. Food and Drug Administration.

3. Chiasma, Inc. (2023). Mycapssa (octreotide) delayed-release capsules prescribing information. U.S. Food and Drug Administration.

4. U.S. Food and Drug Administration. (2024). Orphan drug exclusivity and orphan designation database. https://www.fda.gov/

5. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm